MTOR and neoplasm: The impact of mTOR inhibitors on molecular markers such as p‐S6K1 and p‐4EBP1 in different tissues, including skin, peripheral blood mononuclear cells (PBMCs), and tumor biopsies, has been examined in a number of studies.